Table 3.

Response to first-line chemotherapy prior to inclusion according to FGFR2 fusions status

Responses	FGFR2 fusions			Total
	Positive (n = 4)	Negative (n = 77)	Indeterminate (n = 3)
Complete response (CR)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Partial response (PR)	0 (0.0%)	11 (14.3%)	1 (33.3%)	12 (14.3%)
Stable disease (SD)	1 (25.0%)	25 (32.5%)	1 (33.3%)	27 (32.1%)
Non-CR/Non-PD	0 (0.0%)	1 (1.3%)	0 (0.0%)	1 (1.2%)
Progressive disease (PD)	1 (25.0%)	14 (18.2%)	0 (0.0%)	15 (17.9%)
Not evaluable (NE)	2 (50.0%)	26 (33.8%)	1 (33.3%)	29 (34.5%)
Response rate (CR + PR)	0 (0.0%)	11 (14.3%)	1 (33.3%)	12 (14.3%)
95% confidence interval (%)	[0.0, 49.0]	[8.2, 23.8]	[6.1, 79.2]	[8.4, 23.3]
Disease control rate (CR + PR + SD + Non-CR/Non-PD)	1 (25.0%)	37 (48.1%)	2 (66.7%)	40 (47.6%)
95% confidence interval (%)	[4.6, 69.9]	[37.3, 59.0]	[20.8, 93.9]	[37.3, 58.2]

Analysis set: FLCS.